Late Breaking Abstract - Remdesivir reduces progression to ICU in patients hospitalized with COVID-19
Rikisha Gupta(Gilead Sciences (United States)), Anand P. Chokkalingam(Berkeley Public Health Division), Mazin Abdelghany(University of California, San Francisco), Celine Der-Torossian(Gilead Sciences (United States)), Gina Brown(Imperial College Healthcare NHS Trust), Jason F. Okulicz(Gilead Sciences (United States)), Eunyoung Lee(Gilead Sciences (United States)), Mark Berry(Gilead Sciences (United States)), Valentina Shvachko(Gilead Sciences (United States))
Cited by 0
Related Papers
Assessment of cumulative evidence on genetic associations: interim guidelines
|International Journal of Epidemiology|2007|549
Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy
|New England Journal of Medicine|2013|358
Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long‐Term Nonprogressors in the US Department of Defense HIV Natural History Study
|The Journal of Infectious Diseases|2009|305
A road map for efficient and reliable human genome epidemiology
|Nature Genetics|2006|244
Epidemiology and clinical characteristics of elite controllers
|Current Opinion in HIV and AIDS|2011|176